全文获取类型
收费全文 | 3952篇 |
免费 | 330篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 128篇 |
妇产科学 | 108篇 |
基础医学 | 636篇 |
口腔科学 | 60篇 |
临床医学 | 411篇 |
内科学 | 1045篇 |
皮肤病学 | 147篇 |
神经病学 | 313篇 |
特种医学 | 111篇 |
外国民族医学 | 2篇 |
外科学 | 631篇 |
综合类 | 18篇 |
预防医学 | 222篇 |
眼科学 | 67篇 |
药学 | 174篇 |
中国医学 | 3篇 |
肿瘤学 | 194篇 |
出版年
2023年 | 22篇 |
2022年 | 18篇 |
2021年 | 120篇 |
2020年 | 77篇 |
2019年 | 144篇 |
2018年 | 153篇 |
2017年 | 85篇 |
2016年 | 94篇 |
2015年 | 95篇 |
2014年 | 164篇 |
2013年 | 186篇 |
2012年 | 270篇 |
2011年 | 292篇 |
2010年 | 147篇 |
2009年 | 123篇 |
2008年 | 189篇 |
2007年 | 211篇 |
2006年 | 183篇 |
2005年 | 181篇 |
2004年 | 163篇 |
2003年 | 173篇 |
2002年 | 145篇 |
2001年 | 88篇 |
2000年 | 79篇 |
1999年 | 72篇 |
1998年 | 17篇 |
1997年 | 25篇 |
1996年 | 21篇 |
1995年 | 22篇 |
1993年 | 22篇 |
1992年 | 60篇 |
1991年 | 53篇 |
1990年 | 35篇 |
1989年 | 44篇 |
1988年 | 45篇 |
1987年 | 45篇 |
1986年 | 37篇 |
1985年 | 29篇 |
1984年 | 24篇 |
1983年 | 19篇 |
1982年 | 25篇 |
1981年 | 25篇 |
1980年 | 23篇 |
1979年 | 22篇 |
1976年 | 20篇 |
1975年 | 14篇 |
1974年 | 11篇 |
1973年 | 15篇 |
1972年 | 15篇 |
1971年 | 15篇 |
排序方式: 共有4297条查询结果,搜索用时 15 毫秒
1.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
2.
Maxime Lafond Shin Yoshizawa Shin‐ichiro Umemura 《Journal of ultrasound in medicine》2019,38(3):567-580
Sonodynamic therapy (SDT) consists of the synergetic interaction between ultrasound and a chemical agent. In SDT, the cytotoxicity is triggered by ultrasonic stimuli, notably through cavitation. The unique features of SDT are relevant in the clinical context more than ever: the need for efficacy, accuracy, and safety while being noninvasive and preserving the patient's quality of life. However, despite the promising results of this technique, only a few clinical reports describe the use of SDT. The objective of this article is to provide an extensive overview of the clinical and preclinical research conducted in vivo on SDT, to identify the limitations, and to detail the developed strategies to overcome them. 相似文献
3.
Alberto Addis Maxime Gaasch Alois J Schiefecker Mario Kofler Bogdan Ianosi Verena Rass Anna Lindner Gregor Broessner Ronny Beer Bettina Pfausler Claudius Thom Erich Schmutzhard Raimund Helbok 《Journal of cerebral blood flow and metabolism》2021,41(2):359
Elevated body temperature (Tcore) is associated with poor outcome after subarachnoid hemorrhage (SAH). Brain temperature (Tbrain) is usually higher than Tcore. However, the implication of this difference (Tdelta) remains unclear. We aimed to study factors associated with higher Tdelta and its association with outcome. We included 46 SAH patients undergoing multimodal neuromonitoring, for a total of 7879 h of averaged data of Tcore, Tbrain, cerebral blood flow, cerebral perfusion pressure, intracranial pressure and cerebral metabolism (CMD). Three-months good functional outcome was defined as modified Rankin Scale ≤2. Tbrain was tightly correlated with Tcore (r = 0.948, p < 0.01), and was higher in 73.7% of neuromonitoring time (Tdelta +0.18°C, IQR −0.01 – 0.37°C). A higher Tdelta was associated with better metabolic state, indicated by lower CMD-glutamate (p = 0.003) and CMD-lactate (p < 0.001), and lower risk of mitochondrial dysfunction (MD) (OR = 0.2, p < 0.001). During MD, Tdelta was significantly lower (0°C, IQR −0.2 – 0.1; p < 0.001). A higher Tdelta was associated with improved outcome (OR = 7.7, p = 0.002). Our study suggests that Tbrain is associated with brain metabolic activity and exceeds Tcore when mitochondrial function is preserved. Further studies are needed to understand how Tdelta may serve as a surrogate marker for brain function and predict clinical course and outcome after SAH. 相似文献
4.
Anne Tournadre Bruno Pereira Laure Gossec Martin Soubrier Maxime Dougados 《Joint, bone, spine : revue du rhumatisme》2019,86(1):55-60
Objectives
To analyze the factors associated with fatigue focusing on comorbidities in a large cohort of rheumatoid arthritis (RA).Methods
Cross-sectional analyses were performed on RA patients from the French COMEDRA cohort study, a nurse-led program for comorbidities management. Fatigue was assessed using Question 3 of the Rheumatoid Arthritis Impact of Disease (RAID) score on a 0–10 numerical rating scale (NRS). Fatigue was defined as acceptable if?≤?2, moderate if 3 or 4, or severe if?≥?5 out of 10. Using univariate and multivariate models, the relationship between fatigue and demographics, social, disease characteristics, comorbidities (cardiovascular, infections, cancer, pulmonary, osteoporosis, and psychiatric disorders), physical activity, quality of life, and treatments was investigated.Results
In total, 962 patients were analyzed. The mean fatigue score was 3.8?±?2.7, 40% of patients reported severe fatigue. Patients had an average of 1.8 additional morbid conditions, with anxiety/depression the most common (52%). In univariate analysis, severe fatigue was more frequent in women, in patients not working, and in those with less physical activity. It was associated with disease duration and activity, mHAQ, pain, sleeping and emotional difficulties. Severe fatigue correlated with Multimorbidity index assessing the number of morbid conditions and was associated with obesity, hypertension, COPD, and anxiety/depression. In multivariate models, the risk of severe fatigue was associated with female gender, disease activity, mHAQ, current treatment with NSAIDs and biologics, multimorbidity, obesity and anxiety/depression.Conclusions
Assessment of comorbidities, psychological health and physical activity should be taken into account in order to address frequent RA-related severe fatigue. 相似文献5.
Noemie Luong-Gardiol Imran Siddiqui Irene Pizzitola Beena Jeevan-Raj Mélanie Charmoy Yun Huang Anja Irmisch Sara Curtet Georgi S. Angelov Maxime Danilo Mélanie Juilland Beat Bornhauser Margot Thome Oliver Hantschel Yves Chalandon Gianni Cazzaniga Jean-Pierre Bourquin Joerg Huelsken Werner Held 《Cancer cell》2019,35(4):649-663.e10
6.
7.
8.
9.
10.
Cromb Amandine Le Loarer Franois Sitbon Maxime Italiano Antoine Stoeckle Eberhard Buy Xavier Kind Michle 《European radiology》2020,30(5):2413-2424
European Radiology - The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification... 相似文献